Table 1.
Patient biologic characteristics and treatment efficacy
| Patient | RAS | BRAF | GEP | IMMETCOLS | BOR | Survival (months) |
|---|---|---|---|---|---|---|
| 01–001 | Wild-type | Wild-type | Not evaluated | Not evaluated | SD | DOD (19) |
| 01–003 | Wild-type | V600E | High | 3 | HPD | DOD (4) |
| 01–004 | Wild-type | Wild-type | Low | 3 | HPD | DOD (4) |
| 01–007 | Wild-type | Wild-type | High | 3 | PD | DOD (15) |
| 01–008 | Wild-type | Wild-type | Not evaluated | Not evaluated | SD | AWD (23 +) |
| 01–009 | G12V | Wild-type | Low | 3 | PD | DOD (18) |
| 01–011 | Wild-type | Wild-type | Low | 3 | SD | DOD (10) |
| 01–012 | Wild-type | Wild-type | High | 1 | PD | DOD (20) |
| 02–002 | G12V | Wild-type | Low | 1 | PD | DOD (17) |
| 02–003 | Mutant* | Wild-type | Low | 3 | HPD | DOD (5) |
| 02–005 | G12V | Wild-type | Low | 3 | PD | DOD (12) |
| 04–001 | Wild-type | Wild-type | High | 3 | PD | DOD (14) |
| 05–001 | G12A | Wild-type | High | 3 | PD | DOD (11) |
| 05–002 | Wild-type | Wild-type | Low | 1 | HPD | DOD (9) |
| 05–004 | G13D | Wild-type | Low | 3 | PD | DOD (21) |
| 05–005 | G12A | Wild-type | Not evaluated | Not evaluated | PD | DOD (9) |
| 05–006 | G12D | Wild-type | Not evaluated | Not evaluated | SD | DOD (15) |
| 09–001 | G12S | Wild-type | High | 3 | PD | DOD (6) |
| 09–002 | Mutant* | Wild-type | Low | 3 | NE | DOD (3) |
Bold values indicate patients with hyper-progressive disease
HPD Hyper-progressive disease
*not specified RAS mutation